Bedaquiline plus delamanid for XDR tuberculosis

The combination was initiated in a patient in whom an effective treatment cannot be designed, in the consideration that its potential life-saving benefits outweigh its unknown adverse event risks; in a department in which more than 100 tuberculosis cases a year are admitted to hospital, of which 14...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:The Lancet infectious diseases Ročník 16; číslo 3; s. 294
Hlavní autoři: Lachâtre, Marie, Rioux, Christophe, Dû, Damien Le, Fréchet-Jachym, Mathilde, Veziris, Nicolas, Bouvet, Elisabeth, Yazdanpanah, Yazdan
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States Elsevier Ltd 01.03.2016
Elsevier Limited
Témata:
Antitubercular Agents - therapeutic use
Diarylquinolines - therapeutic use
Extensively Drug-Resistant Tuberculosis - drug therapy
Extensively Drug-Resistant Tuberculosis - surgery
Health Services Accessibility
Humans
Infectious Disease
Infectious diseases
Male
Mycobacterium
Nitroimidazoles - therapeutic use
Oxazoles - therapeutic use
Tuberculosis
ISSN:1473-3099, 1474-4457, 1474-4457
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:The combination was initiated in a patient in whom an effective treatment cannot be designed, in the consideration that its potential life-saving benefits outweigh its unknown adverse event risks; in a department in which more than 100 tuberculosis cases a year are admitted to hospital, of which 14 cases are multidrug-resistant or XDR disease; after a multisciplinary consultation at the national level; and after patient's informed consent. Conditions for this combination use described by Alberto Matteelli and colleagues2 were therefore fulfilled. [...]this combination was initiated under close cardiac monitoring and was well tolerated over a 6 month period.
Bibliografie:SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
content type line 14
ObjectType-Commentary-2
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:1473-3099
1474-4457
1474-4457
DOI:10.1016/S1473-3099(16)00047-5